These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 21536923)

  • 1. FDA cGMP requirements for PET drugs.
    Norenberg JP; Schwarz S; VanBrocklin H
    J Nucl Med; 2011 May; 52(5):16N. PubMed ID: 21536923
    [No Abstract]   [Full Text] [Related]  

  • 2. Final PET CGMP regulation.
    Breslow K; Schwarz SW
    J Nucl Med; 2010 Mar; 51(3):15N-6N. PubMed ID: 20197439
    [No Abstract]   [Full Text] [Related]  

  • 3. Revocation of regulation on positron emission tomography drug products--FDA. Final rule; revocation.
    Fed Regist; 1997 Dec; 62(244):66522. PubMed ID: 10179303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current good manufacturing practice for positron emission tomography drugs.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Dec; 74(236):65409-36. PubMed ID: 20169678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What is now current good manufacturing practice for PET drugs?
    Harolds J
    Clin Nucl Med; 2010 May; 35(5):329. PubMed ID: 20395704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The future of USP monographs for PET drugs.
    Schwarz S; Norenberg J; Berridge M; Dragotakes S; Hung J; Link J; Mason NS; Mattmuller S; Nickel RA; Packard A; Paolino J; Petry N; Ponto J; Quinton TM; Seifert KL; Swanson D; Weiner RE; Zigler S
    J Nucl Med; 2013 Mar; 54(3):472-5. PubMed ID: 23264689
    [No Abstract]   [Full Text] [Related]  

  • 7. Current good manufacturing practices for PET drug products in the United States.
    Swanson D; Graham M; Heinonen TM; Libby P; Mills GQ
    J Nucl Med; 2009 Aug; 50(8):26N-8N. PubMed ID: 19652213
    [No Abstract]   [Full Text] [Related]  

  • 8. CGMP for PET drugs: important steps to take now.
    Vanbrocklin H; Schwarz S
    J Nucl Med; 2010 Dec; 51(12):17N. PubMed ID: 21098789
    [No Abstract]   [Full Text] [Related]  

  • 9. Food and Drug Administration requirements for testing and approval of new radiopharmaceuticals.
    Harapanhalli RS
    Semin Nucl Med; 2010 Sep; 40(5):364-84. PubMed ID: 20674596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Operation of a radiopharmacy for a clinical trial.
    Norenberg JP; Petry NA; Schwarz S
    Semin Nucl Med; 2010 Sep; 40(5):347-56. PubMed ID: 20674594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulatory Requirements for PET Drug Production.
    Schwarz SW; Dick D; VanBrocklin HF; Hoffman JM
    J Nucl Med; 2014 Jul; 55(7):1132-7. PubMed ID: 24914057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nuclear medicine wins decision in FDA PET case.
    Nichols D
    J Nucl Med; 1997 Dec; 38(12):23N. PubMed ID: 9430453
    [No Abstract]   [Full Text] [Related]  

  • 13. Regulations for in vivo radiopharmaceuticals used for diagnosis and monitoring--FDA. Proposed rule.
    Fed Regist; 1998 May; 63(99):28301-9. PubMed ID: 10179873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Foreign Establishment Registration and United States agent requirements.
    Nolte CJ; McNamara-Cullinane M
    Med Device Technol; 2002 Dec; 13(10):32-3. PubMed ID: 12575528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transforming an Academic Radiochemistry Facility for Positron Emission Tomography Drug cGMP Compliance.
    Zhu S; Mosessian S; Kroeger K; Sadeghi S; Slavik R; Kinloch S; Moore M; Allen-Auerbach M; Czernin J; Phelps M
    Mol Imaging Biol; 2020 Apr; 22(2):256-264. PubMed ID: 31240531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulations for in vivo radiopharmaceuticals used for diagnosis and monitoring; extension of comment period--FDA. Proposed rule; extension of comment period.
    Fed Regist; 1998 Aug; 63(148):41219-20. PubMed ID: 10181522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Congress passes FDA reform act: nuclear medicine community stands to gain.
    Kotz D
    J Nucl Med; 1998 Jan; 39(1):15N-16N, 18N. PubMed ID: 9443722
    [No Abstract]   [Full Text] [Related]  

  • 18. Instrumentation and radiopharmaceutical validation.
    Zigler SS
    Q J Nucl Med Mol Imaging; 2009 Aug; 53(4):402-10. PubMed ID: 19834450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. USP and PET radiopharmaceuticals: 1997 FDAMA puts standard-setting body at center of regulatory process.
    Hung JC; Callahan RJ
    J Nucl Med; 2004 Jan; 45(1):13N-14N, 16N. PubMed ID: 14734661
    [No Abstract]   [Full Text] [Related]  

  • 20. The radioactive drug research committee: Background and retrospective study of reported research data (1975-2004).
    Suleiman OH; Fejka R; Houn F; Walsh M
    J Nucl Med; 2006 Jul; 47(7):1220-6. PubMed ID: 16818959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.